Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05954507

Prospective Comparative Multicenter Study Evaluating the Prognostic Value of PET/MRI in Cardiac Sarcoidosis

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-04-02

180

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Cardiac damage is a major cause of death in patients with sarcoidosis, second only to lung damage. Researchers are studying the use of combined PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) scans as a way to better diagnose and predict the progression of cardiac sarcoidosis. This approach aims to improve risk assessment, especially for sudden death, and to help guide therapies and device implantation. Participants with suspected cardiac sarcoidosis will undergo PET/MRI scans using a new hybrid camera that conducts FDG positron emission tomography along with gadolinium-enhanced MRI. This diagnostic method may help distinguish between fibrotic scarring and active granulomatous lesions and assess how patients respond to treatment. The study is prospective and comparative, involving multiple centers. During the study, researchers will monitor participants for up to 24 months, tracking occurrences of severe heart-related events. They will assess diagnostic accuracy, compare imaging results before and after treatment at 3 and 12 months, and evaluate metabolic activity and tissue changes. The study involves consented adults with sarcoidosis who have signs or symptoms suggesting cardiac involvement. Regular follow-up includes imaging assessments and clinical monitoring to evaluate prognosis and therapeutic response.

CONDITIONS

Brief Title

Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Sarcoidosis diagnosed according to ATS/ERS/WASOG criteria
  • Suspicion of cardiac involvement based on symptoms like syncope, palpitations, or heart failure signs
  • Presence of cardiac rhythm or conduction disorders such as Mobitz type 2 AV block, ventricular arrhythmias, or bundle branch block
  • Compatible cardiac ultrasound abnormalities like left ventricular dilation or segmental wall motion abnormalities
  • Informed consent provided
  • Membership in a social security scheme
Not Eligible

You will not qualify if you...

  • Uncontrolled psychiatric illness
  • Claustrophobia
  • Known pregnancy or breastfeeding
  • Unbalanced diabetes affecting carbohydrate metabolism
  • Previous heart attack or known coronary disease
  • Allergy to gadolinium, fluoro-desoxyglucose, or their components
  • Severe kidney impairment (clearance less than 30 mL/min/1.73m2)
  • Implanted pacemakers or devices incompatible with 3 Tesla MRI
  • Presence of certain metallic implants or electronic medical devices
  • Inability or refusal to follow a low-carbohydrate diet and fasting before imaging
  • Inability to hold breath for 10 seconds
  • Legal restrictions like judicial or administrative detention
  • Under legal protection such as guardianship or curatorship
  • Participation in other interventional research or within exclusion period after such research
  • Patients under AME program
  • Positive pregnancy test after consent for women of reproductive age

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 24 months

Participants undergo PET/MRI imaging to evaluate cardiac sarcoidosis and assess prognostic markers.

Assessments at baseline and follow-up imaging up to 24 months

Trial Site Locations

Total: 1 location

1

Henri Mondor Hospital

Créteil, France

Actively Recruiting

Loading map...

Research Team

V

Vania TACHER, PHD

S

Samia BALOUL

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor ...

Acute Cellular Graft Rejection

Actively Recruiting

1 location

Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial...

Cardiac Sarcoidosis

Actively Recruiting

30 locations

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging ...

Heart Failure With Preserved Ejection Fraction

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here